Effects of nomifensine, an inhibitor of endogenous catecholamine re‐ uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man.

Scanlon, M. F.; Gómez-Pan, A.; Mora, B.; Cook, DB; Dewar, J.; Hildyard, A.; Weightman,; Dc, Evered; Hall, R.

doi:10.1111/j.1365-2125.1977.tb05752.x

Cited by 20 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it may be that bromocriptine and metergoline inhibit the prolactin-releasing action of cimetidine by acting directly at the pituitary level, a site of action that is not shared by nomifen¬ sine (Schacht et al 1977). This explanation is consistent with reports demonstrating that nomi¬ fensine does not blunt the prolactin release in response to synthetic TRH which acts directly on pituitary lactotropes (Scanlon et al 1977). The failure of cyproheptadine to interfere with prolac¬ tin secretion confirms previous data (Delitala et al 1975;Ferrari et al 1976) and indicates that a serotoninergic pathway does not participate in the release of prolactin in response to cimetidine.…”

Section: Discussionsupporting

confidence: 88%

Prolactin secretion in man following acute and long-term cimetidine administration

Masala

Faedda

Satta

et al. 1980

Acta Endocrinologica

View full text Add to dashboard Cite

In 20 patients with duodenal ulcer we measured serum prolactin levels following acute and long-term cimetidine administration. In addition, in 20 healthy volunteers we studied the effect of pre-treatment with bromocriptine, metergoline, nomifensine and cyproheptadine on cimetidine-induced prolactin release. Intravenous cimetidine stimulated prolactin secretion in patients and in normal subjects. In the latter, bromocriptine and metergoline pre-administration blunted the release of prolactin in response to iv cimetidine whereas nomifensine and cyproheptadine were ineffective. Long-term treatment with cimetidine (1.2 g daily for 3 months) had no effect on prolactin secretion in the 20 patients studied. No incidence of gynaecomastia, galactorrhoea or disorders of the menstual cycle was observed.It has been shown that cimetidine, an H2 receptor blocking agent, releases prolactin in man (Carlson & Ippoliti 1977; Bohnet et al. 1978). Moreover, side effects such as gynaecomastia and galactorrhoea have been reported in patients treated with the drug (Hall 1976; Delle Faveetal. 1977; Bateson etal. 1977).We studied the effects of both acute and chronic cimetidine treatment on serum prolactin levels in 20 patients with duodenal ulcers. Additional stu¬ dies were carried out on 20 normal subjects in order to elucidate the mechanism(s) responsible for cimetidine-induced prolactin secretion. Materials and MethodsStudies were performed on 20 healthy volunteers, medi¬ cal students and technicians, aged 19 to 36 years and 20 patients with duodenal ulcer, aged 23 to 38 years. In each group 50 per cent were male. All the patients had an endoscopie diagnosis of duodenal ulcer requiring treat¬ ment with cimetidine. An informed consent was obtained prior to the study. The experiments started at 08.00 h after an overnight fast with the subjects in a recumbent position. A venous cannula was inserted in a forearm vein at least 45 min prior to beginning the study; patency was maintained by a slow infusion of normal saline. After collection of three baseline samples (-30, -15 and 0 min) all subjects received an iv bolus of 200 mg cimetidine (Tagamet®; Smith Kline 8c French, Milan, Italy). Blood was collected 15, 30, 60 and 120 min later. In the volunteers, cimetidine administration was repeated 60 min after giving the following drugs: bromocriptine (2.5 mg p.o.), metergoline (2 mg p.o.), nomifensine (200 mg p.o.) and cyproheptadine (8 mg p.o.). A 3 day interval elapsed between each test which was performed exactly as described above. The patients were treated with cimetidine, 400 mg p.o., t.i.d. for 3 months. Blood samples were obtained weekly from each patient, at 08.00 h, prior to the administration of the first daily dose.Blood samples for hormone assay were centrifuged and serum specimens stored at -20°C until assayed. All samples from each subject were processed in duplicate in the same assay. Serum prolactin was measured by a specific double-antibody radioimmunoassay (McNeilly 1973). Standard, antiserum and 125I-labelled human pro¬...

show abstract

Section: Discussionsupporting

confidence: 88%

Prolactin secretion in man following acute and long-term cimetidine administration

Masala

Faedda

Satta

et al. 1980

Acta Endocrinologica

View full text Add to dashboard Cite

show abstract

“…Yet, discordant results about the endocrine effects of nomifensine in man have been published. Scanlon et al (1977) were unable to demonstrate a reduction in prolactin levels in either normal subjects or patients with hyperprolactinaemia following short-term treatment with the drug. Muller et al (1978), on the contrary, found nomifensine significantly lowered prolactin levels and proposed its use as a diagnostic aid in differential diagnosis of hyperprolactinaemic states due to a pituitary microadenoma.…”

mentioning

confidence: 87%

Inhibition of Prolactin Secretion by Nomifensine in Man

Masala

Devilla

Delitala

et al. 1980

Clinical Endocrinology

View full text Add to dashboard Cite

Serum prolactin, TSH and GH levels were measured in thirty healthy volunteers in fasting conditions and following oral administration of 200 mg nomifensine. In addition, the effect of the drug on serum prolactin and TSH response to synthetic TRH was studied in twenty normal subjects. Inhibition of endogenous catecholamine reuptake by nomifensine significantly inhibited prolactin release whereas it had no effect on TSH and GH levels. Nomifensine administration had no appreciable effect on the TRH-induced release of TSH and prolactin.

show abstract

“…The present studies confirm that nomifensine does not decrease the basal PRL in patients with prolactinoma and idiopathic hyperprolactinemia. Scanlon et al (1977) have reported that nomifensine did not decrease the basal plasma PRL in two acromegalic patients with hyperprolactinemia.…”

Section: Discussionmentioning

confidence: 88%

“…Defective dopaminergic transmission in the central nervous system has been postulated in patients with prolactin (PRL) secreting pituitary adenoma (prolactinoma) (Muller et al, 1978, Scanlon et al, 1977. Nomifensine, a drug which activates dopamine neurotransmission by inhibiting dopamine reuptake and/or by dopamine release, does not alter plasma PRL levels in patients with prolactinoma (Muller et al, 1978, Camanni et al, 1980.…”

mentioning

confidence: 99%

Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.

et al. 1985

View full text Add to dashboard Cite

We undertook this study, because conflicting data were reported about the dopaminergic regulation of prolactin (PRL) secretion in patients with acromegaly and hyperprolactinemia. In order to clarify the dopaminergic regulation of PRL secretion in patients with acromegaly and hyperprolactinemia, the effects of nomifensine, a central dopamine agonist, FK 33-824, a centrally antidopaminergically acting agent, and domperidone, a peripheral dopamine antagonist, on plasma PRL in these patients were studied. The results were compared with those observed in normal subjects and hyperprolactinemic patients, with or without a pituitary tumor. Nomifensine did not lower the PRL levels and FK 33-824 did not raise the PRL levels in acromegalic patients. In hyperprolactinemic patients, nomifensine did not lower the PRL levels and FK 33-824 failed to raise the PRL levels. Domperidone did not increase PRL in about a third of acromegalic patients, while TRH increased PRL in the all normoprolactinemic acromegalic patients. These results suggest that in acromegalic patients there may be a disturbance in dopamine related neurotransmission and that such disorders also seem to be present in patients with hyperprolactinemia, with or without a pituitary tumor.

show abstract

Effects of nomifensine, an inhibitor of endogenous catecholamine re‐ uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man.

Cited by 20 publications

References 32 publications

Prolactin secretion in man following acute and long-term cimetidine administration

Prolactin secretion in man following acute and long-term cimetidine administration

Inhibition of Prolactin Secretion by Nomifensine in Man

Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.

Contact Info

Product

Resources

About